| abstract |
Novel insulin compounds having a desirably protracted insulin action and/or antigenicity are provided. The novel insulin compounds are represented by formula (II), wherein E individually represents Glu or a neutral amino acid residue which can be coded for by nucleotide sequences, N represents an amino acid residue which can be coded for by nucleotide sequences, T represents Thr or Arg, X represents Thr, Ser, Ala or OH, and Y represents OR or NR1R2, where R, R?1 and R2¿ individually represents hydrogen or lower alkyl, but is not present when X represents OH. |